8-KLeadership ChangesExhibits & Filings

CME GROUP INC. 8-K Report, Executive Changes (Mar 7, 2024)

Filed March 7, 2024For Securities:CME

Summary

CME Group Inc. (CME) filed an 8-K on March 7, 2024, to report an amendment to its Omnibus Stock Plan. Effective March 1, 2024, the Compensation Committee approved an amended and restated Omnibus Stock Plan that introduces "double trigger" change of control vesting provisions. This change aligns the company's executive compensation practices with current market standards and addresses shareholder preferences. The key change involves the acceleration of equity award vesting upon a "Change of Control." This acceleration will only occur if specific conditions are met, namely if the acquiring entity does not provide equivalent replacement awards or if it does provide replacement awards but the executive is involuntarily terminated without Cause or for Good Reason within 24 months of the change in control. This modification aims to provide enhanced security for executive compensation in potential acquisition scenarios while ensuring alignment with shareholder interests.

Key Highlights

  • 1CME Group amended and restated its Omnibus Stock Plan, effective March 1, 2024.
  • 2The amendment introduces "double trigger" change of control vesting provisions for equity awards.
  • 3This change aligns compensation practices with market standards and shareholder preferences.
  • 4Vesting acceleration will occur if the surviving entity does not provide qualifying replacement awards.
  • 5Vesting acceleration also occurs if replacement awards are provided, but the executive experiences an involuntary termination without Cause or for Good Reason within 24 months post-Change of Control.
  • 6The amended plan replaces the previous Third Amended and Restated Omnibus Stock Plan.
  • 7The full text of the Amended Omnibus Stock Plan is included as an exhibit to the filing.

Frequently Asked Questions